Clinical scale mRNA manufacturing

The Victorian - BioNTech partnership

mRNA Victoria has partnered with BioNTech to establish a state-of-the-art clinical and R&D manufacturing facility at La Trobe University’s Bundoora campus and support research translation and commercialisation of local research. This partnership also sees BioNTech establishing its Headquarters and Innovation Centre in Melbourne, bringing AI capability to Australia and delivering a significant 10-year Cancer Clinical Trial Program to bring next generation cancer treatments to up to 4,000 patients.

Manufacturing – mRNA GMP clinical and research grade manufacturing facility

BioNTech is establishing a clinical scale mRNA manufacturing facility at La Trobe University’s Bundoora campus.

The new facility will produce next generation mRNA vaccines and treatments (including oncology treatments) for clinical trials for medical research institutes, biotech and life science companies, as well as BioNTech’s own investigational drug and vaccine candidate products. It will also produce research grade RNA materials for Australian researchers to develop early stage and clinical vaccines and therapies in their laboratories.

The BioNTech Clinical Manufacturing Facility is an anchor tenant for the La Trobe University City of the Future, a $5 billion precinct transforming the Bundoora Campus.

Construction of the facility commenced in mid 2024.

If you are a research team or biotech interested in clinical manufacturing and research-grade RNA, please contact the mRNA Victoria team.

Research and Development

Under the multi-layered strategic partnership between BioNTech and mRNA Victoria, BioNTech has also established an Innovation Centre in Melbourne to support the translation and commercialisation of local research, helping to fast-track new therapies from lab to patients. The Innovation Centre supports local researchers and biotech companies to tap into BioNTech’s world-leading expertise in developing immunotherapies.

BioNTech and its Artificial Intelligence subsidiary, InstaDeep are also working with local research partners to deliver enhancements to the Epidemiological Surveillance for Research and Analytics (ESRA) tool and potentially expand its application to allow Victorian researchers to support better identification and treatment of potential future pandemics and other diseases.

Clinical Cancer Program

As part of the strategic partnership with mRNA Victoria, BioNTech is also delivering the BioNTech Clinical Cancer Program to deliver next generation precision oncology treatments to up to 4,000 cancer patients in the next 10 years. Led by the Peter MacCallum Cancer Centre as coordinating delivery partner with Monash Health, Alfred Health, Austin Health, and Omico as initial delivery partners, the program will work with local hospitals and health providers to deliver new treatments for hard-to-treat cancers.